Literature DB >> 12047983

Treatment interventions for Parkinson's disease: an evidence based assessment.

Olivier Rascol1, Christopher Goetz, William Koller, Werner Poewe, Cristina Sampaio.   

Abstract

We did a systematic review, with a uniform method of assessment of efficacy and safety, to assess the different interventions available for the management of Parkinson's disease (drugs, surgical interventions, and physical treatments) with respect to the following indications: prevention of disease progression, symptomatic treatment of motor features (parkinsonism), symptomatic control of motor complications, prevention of motor complications, and symptomatic treatment of non-motor features. Our aim was not to define practice guidelines, but rather to improve clinicians' knowledge of the presently available published clinical evidence, based mainly on randomised controlled trials. We hope that our review will help doctors to incorporate this background into their own decision-making strategy to make appropriate choices with respect to the treatment of individual patients with Parkinson's disease.

Entities:  

Mesh:

Year:  2002        PMID: 12047983     DOI: 10.1016/S0140-6736(02)08520-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  50 in total

Review 1.  Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.

Authors:  Judith Dams; Bernhard Bornschein; Jens Peter Reese; Annette Conrads-Frank; Wolfgang H Oertel; Uwe Siebert; Richard Dodel
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

Review 2.  Evaluating drug treatments for Parkinson's disease: how good are the trials?

Authors:  Keith Wheatley; Rebecca L Stowe; Carl E Clarke; Robert K Hills; Adrian C Williams; Richard Gray
Journal:  BMJ       Date:  2002-06-22

Review 3.  Current concepts in the diagnosis and management of Parkinson's disease.

Authors:  Mark Guttman; Stephen J Kish; Yoshiaki Furukawa
Journal:  CMAJ       Date:  2003-02-04       Impact factor: 8.262

4.  Using monoamine oxidase type B inhibitors in Parkinson's disease.

Authors:  Yoav Ben-Shlomo; Kailash Bhatia
Journal:  BMJ       Date:  2004-09-11

Review 5.  Alternatives to levodopa in the initial treatment of early Parkinson's disease.

Authors:  Andrew Lees
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 6.  Rivastigmine in Parkinson's disease dementia: profile report.

Authors:  M Asif A Siddiqui; Antona J Wagstaff
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

7.  Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression.

Authors:  Cristina Sampaio; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2010-03       Impact factor: 42.937

8.  Drug-related problems in Parkinson's disease: the role of community pharmacists in primary care.

Authors:  Sabrina Schröder; Peter Martus; Per Odin; Marion Schaefer
Journal:  Int J Clin Pharm       Date:  2011-06-28

Review 9.  Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.

Authors:  Angelo Antonini; K Ray Chaudhuri; Pablo Martinez-Martin; Per Odin
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

10.  Prodromal non-motor symptoms of Parkinson's disease.

Authors:  Clelia Pellicano; Dario Benincasa; Vincenzo Pisani; Francesca R Buttarelli; Morena Giovannelli; Francesco E Pontieri
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.